title: Dynamics of bivalent chromatin domains upon drug induced reactivation and resilencing in cancer cells.
abstract: Epigenetic deregulation revealed by altered profiles of DNA methylation and histone modifications is a frequent event in cancer cells and results in abnormal patterns of gene expression. Cancer silenced genes constitute prime therapeutic targets and considerable progress has been made in the epigenetic characterization of the chromatin scenarios associated with their inactivation and drug induced reactivation. Despite these advances, the mechanisms involved in the maintenance or resetting of epigenetic states in both physiological and pharmacological situations are poorly known. To get insights into the dynamics of chromatin regulation upon drug-induced reactivation, we have investigated the epigenetic profiles of two chromosomal regions undergoing long range epigenetic silencing in colon cancer cells in time-course settings after exposure of cells to chromatin reactivating agents. The DNA methylation states and the balance between histone H3K4 methylation and H3K27 methylation marks clearly define groups of genes with alternative responses to therapy. We show that the expected epigenetic remodeling induced by the reactivating drugs, just achieves a transient disruption of the bivalent states, which overcome the treatment and restore the transcriptional silencing approximately four weeks after drug exposure. The interplay between DNA methylation and bivalent histone marks appears to configure a plastic but stable chromatin scenario that is fully restored in silenced genes after drug withdrawal. These data suggest that improvement of epigenetic therapies may be achieved by designing strategies with long lasting effects.
authors.affiliation: Institut de Medicina Predictiva i Personalitzada del Càncer, Badalona, Barcelona, Spain.
authors.forename: Regina
authors.initials: R
authors.lastname: Mayor
authors.forename: Mar
authors.initials: M
authors.lastname: Muñoz
authors.forename: Marcel W
authors.initials: MW
authors.lastname: Coolen
authors.forename: Joaquin
authors.initials: J
authors.lastname: Custodio
authors.forename: Manel
authors.initials: M
authors.lastname: Esteller
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Clark
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Peinado
mesh_terms: D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D002843:Chromatin / Q000737:chemistry / Q000187:drug effects*; D002889:Chromosomes, Human, Pair 2 / Q000737:chemistry / Q000235:genetics; D002893:Chromosomes, Human, Pair 3 / Q000737:chemistry / Q000235:genetics; D003110:Colonic Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000235:genetics; D018899:CpG Islands; D019175:DNA Methylation; D000077209:Decitabine; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D045325:HCT116 Cells; D006657:Histones / Q000737:chemistry / Q000235:genetics; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D028322:Inhibin-beta Subunits / Q000737:chemistry / Q000235:genetics; D056484:Jumonji Domain-Containing Histone Demethylases / Q000737:chemistry; D013997:Time Factors; D015533:Transcriptional Activation
chemical_list: D002843:Chromatin; D006657:Histones; D006877:Hydroxamic Acids; C422402:INHBB protein, human; C012589:trichostatin A; D000077209:Decitabine; D028322:Inhibin-beta Subunits; D056484:Jumonji Domain-Containing Histone Demethylases; D001374:Azacitidine